The PCSK9* inhibitor alirocumab reduced low-density lipoprotein cholesterol (LDL-C) levels and several other lipid parameters in patients with type 2 diabetes (T2D) and high cardiovascular risk, according to two studies presented at the 77th Scientific Sessions of the American Diabetes Association (ADA 2017) held in San Diego, California, US.
More frequent text messaging responses to reminders to check blood glucose (BG) was associated with better glycaemic control in teens with type 1 diabetes (T1D), and may help the transition from paediatric to adult care which entails greater self-care routine, suggests a study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
A single dose of the human glucagon receptor (GCGR) antibody, REMD-477, reduces the amount of insulin necessary and significantly improves glycaemic control in individuals with type 1 diabetes (T1D), according to a study presented at the ADA 2017 in San Diego, California, US.
Severe obesity in children and adolescents may increase the risk of developing youth-onset diabetes, according to a study presented at the American Diabetes Association’s 77th Scientific Sessions held in San Diego, California, US.
Insulin degludec had comparable cardiovascular safety and reduced the risk of severe hypoglycaemia compared with insulin glargine U100 in patients with type 2 diabetes and high cardiovascular risk, according to results of the DEVOTE* study.
Individuals with high fasting plasma glucose (FPG) lost more weight than those who had low FPG in response to a high-fibre, low glycaemic load diet, suggesting that FPG could be used as a biomarker to predict dietary weight loss success and to guide selection of the most effective diet, in particular for those with prediabetes and diabetes, according to studies presented at ADA 2017.
Tacrolimus is safe and effective in inducing and maintaining remission in paediatric patients with biologic refractory inflammatory bowel disease (IBD), according to a study presented at the 49th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology and Nutrition in Athens, Greece.
Lifetime prevalence of acute pain leading to the use of analgesics approaches 100% in the general population, and pharmacists are a pivotal first point of contact for patients in their journey to better pain management. Noting the need for pharmacists to be more aware of their evolving role as a community pharmacist, GlaxoSmithKline Consumer Healthcare partnered with MIMS Education to organize a workshop that served as a platform for robust knowledge-sharing. Below are highlights from the workshop.